Journal: eLife
Article Title: Neuropeptide Y-expressing dorsal horn inhibitory interneurons gate spinal pain and itch signalling
doi: 10.7554/eLife.86633
Figure Lengend Snippet: ( A ) The experimental approach taken to generate the data presented in ( B, C ). ( B, C ) Vehicle control-treated AAV.flex.hM3Dq-mCherry spinal-injected Npy-Cre mice display marked reductions in mechanical withdrawal threshold (MWT) ( B ) and withdrawal latency to radiant heat ( C ) of the ipsilateral paw 2 days after intraplantar injection of complete Freund’s adjuvant (CFA). Both mechanical and thermal hypersensitivity are blocked in clozapine- N -oxide (CNO)-treated mice ( n = 10 vehicle group, 8 CNO group). ( D ) The experimental approach taken for the data presented in ( E, F ). Drug treatments were administered using a crossover design ( n = 9). ( E, F ) Marked reductions in MWT ( E ) and withdrawal latency to radiant heat ( F ) are observed following spared nerve injury (SNI). These are blocked by CNO treatment, and this blockade persists in the presence of the Y1 antagonist BMS 193885 (BMS). ( G ) The experimental approach taken for the data presented in ( H–J ). Acc. = acclimation; Pre. = pre-conditioning; Con. = conditioning. ( H ) Neither wild-type control nor AAV.flex.hM3Dq-mCherry spinal-injected Npy-Cre mice displayed a conditioned place preference (CPP) to CNO following SNI ( n = 7). ( I ) Heat maps of a representative mouse from each group demonstrating position and time spent in each chamber during preconditioning and post-conditioning test days. ( J ) A marked increase in the time spent responding to application of acetone to the ipsilateral paw (shaking, lifting, and/or licking) is seen in vehicle-treated AAV.flex.hM3Dq-mCherry spinal-injected Npy-Cre mice following SNI. This cold hypersensitivity is blocked when the same mice are treated with CNO ( n = 8). Data are shown as individual values with mean ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; repeated-measures two-way ANOVA with Šidák’s post-test in ( B, C, H ), repeated-measures one-way ANOVA with Šidák’s post-test in ( E , F, J ).
Article Snippet: For some experiments, the Y1 antagonist BMS 193885 (Bio-Techne, Abingdon, UK) dissolved in a 40% PEG-400/60% sterile saline mixture was co-injected i.p. at a dose of 10 mg/kg with CNO; co-injection of the respective vehicles for CNO and BMS 193885 was used as a control.
Techniques: Injection, Adjuvant, Conditioned Place Preference